Form 4: Tarsus Pharmaceuticals Executive Dianne C. Whitfield Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, reports the vesting and settlement of restricted stock units.

Summary

  • On March 15, 2025, Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, reported transactions involving the company's stock.
  • These transactions involved the vesting and settlement of restricted stock units (RSUs).
  • Whitfield acquired 18,885 shares of common stock upon the settlement of vested RSUs.
  • She still directly owns 53,066 shares of common stock.
  • The transactions also involved the vesting of RSUs granted in 2022, 2023 and 2024.
  • After the reported transactions, Whitfield directly owns 4,463 RSUs granted on March 9, 2022, 14,497 RSUs granted on March 8, 2023, and 21,527 RSUs granted on March 7, 2024.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions, with no inherent positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is a common occurrence in publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.

Stakeholder Impact

  • The transactions have a minor impact on shareholders as they reflect the standard compensation practices of the company.

Key Dates

DateDescription
03/09/2022RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan, vesting 25% annually starting March 15, 2023.
03/08/2023RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan, vesting 25% annually starting March 15, 2024.
03/07/2024RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan, vesting 25% annually starting March 15, 2025.
03/15/2025Date of the reported transactions: vesting and settlement of RSUs.
03/18/2025Date of signature by Jeffrey Farrow, Attorney-in-Fact.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.